Lovenox
Phase 3Small molecule
Lovenox is one of 3 small molecule programs targeting Adverse Pregnancy Outcome. It is currently in Phase 3.
2
Indications
8
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in Low Molecular Weight Heparin
#DrugCompanyPhaseTrials
1Lovenox
UUniversity of Monastir
Phase 3
Innohep
Jazz PharmaceuticalsPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Coronary Syndrome3 trials
Complication1 trial
Orthopedic Surgeries1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lovenox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Monastir